Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cash from Financing Activities (2021 - 2025)

Kiniksa Pharmaceuticals International's Cash from Financing Activities history spans 5 years, with the latest figure at $7.7 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 257.52% year-over-year to $7.7 million; the TTM value through Dec 2025 reached $33.0 million, up 169.22%, while the annual FY2025 figure was $33.0 million, 169.22% up from the prior year.
  • Cash from Financing Activities reached $7.7 million in Q4 2025 per KNSA's latest filing, down from $11.9 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $11.9 million in Q3 2025 to a low of -$178000.0 in Q2 2024.
  • Average Cash from Financing Activities over 5 years is $2.8 million, with a median of $1.1 million recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: crashed 212.66% in 2024, then surged 6110.11% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $1.2 million in 2021, then fell by 1.82% to $1.2 million in 2022, then crashed by 41.6% to $695000.0 in 2023, then surged by 208.2% to $2.1 million in 2024, then surged by 257.52% to $7.7 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Cash from Financing Activities are $7.7 million (Q4 2025), $11.9 million (Q3 2025), and $10.7 million (Q2 2025).